ARENTFOX SCHIFF LLP for CSL BEHRING
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Taxation/Internal Revenue Code TAX
Orphan drug exclusion within the pharmaceutical tax in the Patient Protection and Affordable Care Act H.R. 3678 (Preserving Access to Orphan Drugs Act of 2015), all provisions H.R. 22 (FAST Act), potential inclusion of Preserving Access to Orphan Drugs Act H.R. 2029 (Consolidated Appropriations Act, 2016), Division Q, provisions concerning the orphan drug tax credit
Foreign entity interest: CSL Limited, identified in the LD-1, is interested in U.S. tax policies that may affect the business of its subsidiary CSL Behring.
| Lobbyist | Covered position, as disclosed |
|---|---|
| PHILIP ENGLISH | — |
| NORMAN FREDERICK LENT | — |
Budget/Appropriations BUD
H.R. 2029 (Consolidated Appropriations Act, 2016) Division H, regarding inclusion of Alpha-1 report language
Foreign entity interest: CSL Limited, identified in the LD-1, is interested in the existence of funding for programs that may affect the business of its subsidiary CSL Behring.
| Lobbyist | Covered position, as disclosed |
|---|---|
| PHILIP ENGLISH | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.